In last trading session, Virax Biolabs Group Ltd (NASDAQ:VRAX) saw 1.04 million shares changing hands with its beta currently measuring 1.63. Company’s recent per share price level of $1.89 trading at -$0.48 or -20.25% at ring of the bell on the day assigns it a market valuation of $8.20M. That closing price of VRAX’s stock is at a discount of -376.19% from its 52-week high price of $9.00 and is indicating a premium of 68.25% from its 52-week low price of $0.60. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.51 million shares which gives us an average trading volume of 1.79 million if we extend that period to 3-months.

Virax Biolabs Group Ltd (NASDAQ:VRAX) trade information

Upright in the red during last session for losing -20.25%, in the last five days VRAX remained trading in the green while hitting it’s week-highest on Wednesday, 12/18/24 when the stock touched $1.89 price level, adding 20.59% to its value on the day. Virax Biolabs Group Ltd’s shares saw a change of 29.45% in year-to-date performance and have moved 17.39% in past 5-day. Virax Biolabs Group Ltd (NASDAQ:VRAX) showed a performance of -1.56% in past 30-days. Number of shares sold short was 0.45 million shares which calculate 0.11 days to cover the short interests.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -52.25% during past 5 years.

Virax Biolabs Group Ltd (NASDAQ:VRAX)’s Major holders

VIRTU FINANCIAL LLC is the top institutional holder at VRAX for having 28058.0 shares of worth $33000.0. And as of 2024-06-30, it was holding 1.3984 of the company’s outstanding shares.

The second largest institutional holder is HRT FINANCIAL LP, which was holding about 25672.0 shares on 2024-06-30. The number of shares represents firm’s hold over 1.2795 of outstanding shares, having a total worth of $29000.0.